These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1021 related items for PubMed ID: 21173304

  • 1. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J.
    Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH.
    Poulin Y, Crowley JJ, Langley RG, Unnebrink K, Goldblum OM, Valdecantos WC.
    J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):882-90. PubMed ID: 23790018
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM.
    J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
    [Abstract] [Full Text] [Related]

  • 4. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA.
    J Dermatolog Treat; 2007 Sep; 18(1):25-31. PubMed ID: 17365264
    [Abstract] [Full Text] [Related]

  • 5. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
    Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM.
    J Am Acad Dermatol; 2006 Oct; 55(4):598-606. PubMed ID: 17010738
    [Abstract] [Full Text] [Related]

  • 6. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
    Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A.
    Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
    Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J, ABT-874 Psoriasis Study Investigators.
    Arch Dermatol; 2008 Feb; 144(2):200-7. PubMed ID: 18283176
    [Abstract] [Full Text] [Related]

  • 8. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
    Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K.
    J Am Acad Dermatol; 2008 Jan; 58(1):106-15. PubMed ID: 17936411
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
    Am J Clin Dermatol; 2011 Feb 01; 12(1):51-62. PubMed ID: 21110526
    [Abstract] [Full Text] [Related]

  • 10. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K.
    N Engl J Med; 2015 Jul 09; 373(2):136-44. PubMed ID: 26154787
    [Abstract] [Full Text] [Related]

  • 11. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB.
    Ann Intern Med; 2012 Dec 18; 157(12):846-55. PubMed ID: 23247938
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.
    JAMA Dermatol; 2018 Jun 01; 154(6):676-683. PubMed ID: 29799960
    [Abstract] [Full Text] [Related]

  • 13. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.
    J Dermatolog Treat; 2007 Jun 01; 18(6):341-50. PubMed ID: 18058494
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of Adalimumab in the treatment of moderate to severe palmo-plantar psoriasis: an open label study.
    Richetta AG, Mattozzi C, Giancristoforo S, D'Epiro S, Cantisani C, Macaluso L, Salvi M, Calvieri S.
    Clin Ter; 2012 Jun 01; 163(2):e61-6. PubMed ID: 22555836
    [Abstract] [Full Text] [Related]

  • 15. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
    Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S.
    N Engl J Med; 2012 Mar 29; 366(13):1181-9. PubMed ID: 22455412
    [Abstract] [Full Text] [Related]

  • 16. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct 29; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 17. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov 29; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 18. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S.
    J Am Acad Dermatol; 2007 Aug 29; 57(2):269-75. PubMed ID: 17574299
    [Abstract] [Full Text] [Related]

  • 19. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R.
    J Drugs Dermatol; 2011 Apr 29; 10(4):396-402. PubMed ID: 21455550
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
    Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study Group.
    J Dermatol; 2012 Mar 29; 39(3):242-52. PubMed ID: 21955098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.